These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25682203)

  • 21. Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1).
    Jendrny C; Beck-Sickinger AG
    Chembiochem; 2016 Apr; 17(8):719-26. PubMed ID: 26574674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.
    de Veer SJ; Wang CK; Harris JM; Craik DJ; Swedberg JE
    J Med Chem; 2015 Oct; 58(20):8257-68. PubMed ID: 26393374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.
    Santos JA; Kondo MY; Freitas RF; dos Santos MH; Ramalho TC; Assis DM; Juliano L; Juliano MA; Puzer L
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1485-9. PubMed ID: 26848109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imidazopyridine-fused [1,3]diazepinones: modulations of positions 2 to 4 and their impacts on the anti-melanoma activity.
    Baccon-Sollier PL; Malki Y; Maye M; Ali LMA; Lichon L; Cuq P; Vincent LA; Masurier N
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):935-949. PubMed ID: 32249633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors.
    Riley BT; Ilyichova O; de Veer SJ; Swedberg JE; Wilson E; Hoke DE; Harris JM; Buckle AM
    Biochemistry; 2019 May; 58(21):2524-2533. PubMed ID: 31058493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and functional characterization of the human tissue kallikrein 9.
    Filippou PS; Farkona S; Brinc D; Yu Y; Prassas I; Diamandis EP
    Biochem J; 2017 Jul; 474(14):2417-2433. PubMed ID: 28559305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Studies on the Inhibitory Binding Mode of Aromatic Coumarinic Esters to Human Kallikrein-Related Peptidase 7.
    Hanke S; Tindall CA; Pippel J; Ulbricht D; Pirotte B; Reboud-Ravaux M; Heiker JT; Sträter N
    J Med Chem; 2020 Jun; 63(11):5723-5733. PubMed ID: 32374603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of plasma kallikrein inhibitors: functional and structural requirements of plasma kallikrein inhibitors.
    Tsuda Y; Wanaka K; Tada M; Okamoto S; Hijikata-Okunomiya A; Okada Y
    Chem Pharm Bull (Tokyo); 1998 Mar; 46(3):452-7. PubMed ID: 9549887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
    Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
    Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and structure-activity relationship of imidazolinylindole derivatives as kallikrein 7 inhibitors.
    Murafuji H; Muto T; Goto M; Imajo S; Sugawara H; Oyama Y; Minamitsuji Y; Miyazaki S; Murai K; Fujioka H
    Bioorg Med Chem Lett; 2019 Jan; 29(2):334-338. PubMed ID: 30522951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases.
    Laureano AFS; Zani MB; Sant'Ana AM; Tognato RC; Lombello CB; do Nascimento MHM; Helmsing S; Fühner V; Hust M; Puzer L
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127626. PubMed ID: 33096161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.
    Debela M; Hess P; Magdolen V; Schechter NM; Steiner T; Huber R; Bode W; Goettig P
    Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16086-91. PubMed ID: 17909180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of tissue kallikrein inhibitors: importance in cancer.
    Bhoola KD; Misso NL; Naran A; Thompson PJ
    Curr Opin Investig Drugs; 2007 Jun; 8(6):462-8. PubMed ID: 17621876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of kallikrein-related peptidases: An overview.
    Masurier N; Arama DP; El Amri C; Lisowski V
    Med Res Rev; 2018 Mar; 38(2):655-683. PubMed ID: 28609548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the kallikrein-related peptidases for drug development.
    Sotiropoulou G; Pampalakis G
    Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
    de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
    Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.
    de Souza AS; Pacheco BDC; Pinheiro S; Muri EMF; Dias LRS; Lima CHS; Garrett R; de Moraes MBM; de Souza BEG; Puzer L
    Bioorg Med Chem Lett; 2019 May; 29(9):1094-1098. PubMed ID: 30833107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin.
    Ulbricht D; Tindall CA; Oertwig K; Hanke S; Sträter N; Heiker JT
    Biol Chem; 2018 Sep; 399(9):1079-1084. PubMed ID: 29494334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.